Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor Positive，HER2-negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT06781281
What this trial is testing

NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.

Who this might be right for
Breast Cancer Invasive
Henan Cancer Hospital 709
Testing effectiveness (Phase 2)Active Not RecruitingNCT03393845
What this trial is testing

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer
Nancy Chan, MD 47
Very early researchEnded earlyNCT03361800
What this trial is testing

Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC

Who this might be right for
Breast CancerInvasive Breast CancerER-Negative PR-Negative HER2-Negative Breast Cancer
UNC Lineberger Comprehensive Cancer Center 5
Not applicableStudy completedNCT01293032
What this trial is testing

Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

Who this might be right for
Ductal Breast Carcinoma in SituLobular Breast Carcinoma in SituStage II Breast Cancer+4 more
Virginia Commonwealth University 59
Early research (Phase 1)Looking for participantsNCT05683418
What this trial is testing

Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

Who this might be right for
HR+/HER2-negative Breast Cancer
Totus Medicines 241
Not applicableUnknownNCT05870813
What this trial is testing

CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer

Who this might be right for
Breast CancerHER2-negative Breast CancerHormone Receptor Positive Breast Carcinoma
Institut fuer Frauengesundheit 3,000
Testing effectiveness (Phase 2)Study completedNCT01082068
What this trial is testing

Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer

Who this might be right for
Breast Cancer
Sanofi 72
Very early researchEnded earlyNCT00651976
What this trial is testing

Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery

Who this might be right for
Breast Cancer
Vanderbilt-Ingram Cancer Center 213
Large-scale testing (Phase 3)Not Yet RecruitingNCT07061717
What this trial is testing

Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

Who this might be right for
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 474
Not applicableUnknownNCT02597868
What this trial is testing

A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 132
Not applicableStudy completedNCT02023359
What this trial is testing

Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Novartis Healthcare A/S 7
Testing effectiveness (Phase 2)Looking for participantsNCT06875128
What this trial is testing

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

Who this might be right for
Metastatic Breast Cancer in the Liver
Delcath Systems Inc. 90
Early research (Phase 1)Looking for participantsNCT06756932
What this trial is testing

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

Who this might be right for
Hormone-receptor-positive Breast CancerHER2-negative Breast CancerMetastatic Breast Cancer
BeOne Medicines 120
Large-scale testing (Phase 3)Active Not RecruitingNCT02246621
What this trial is testing

Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

Who this might be right for
Breast Cancer
Eli Lilly and Company 493
Testing effectiveness (Phase 2)Looking for participantsNCT07330544
What this trial is testing

A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 118
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07340619
What this trial is testing

Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.

Who this might be right for
Metastatic (Stage IV) Melanoma
UNICANCER 51
Not applicableLooking for participantsNCT07347600
What this trial is testing

Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Locally Advanced Breast CancerMetastatic Breast Cancer
Hoffmann-La Roche 500
Testing effectiveness (Phase 2)Active Not RecruitingNCT06590857
What this trial is testing

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Who this might be right for
Metastatic Breast CancerHER2-negative Breast CancerER+ Breast Cancer+7 more
RayzeBio, Inc. 16
Early research (Phase 1)Ended earlyNCT03128619
What this trial is testing

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeInvasive Breast Carcinoma+14 more
Jonsson Comprehensive Cancer Center 10
Testing effectiveness (Phase 2)Ended earlyNCT03858972
What this trial is testing

Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC

Who this might be right for
Breast Cancer
Odonate Therapeutics, Inc. 152
Next Page